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Prostasin is a serine protease discovered in ejaculated human semen in 1994 (1). The molecular mass of prostasin is 40
kDa when examined by SDS-polyacrylamide gel electrophoresis (PAGE)1 under reducing conditions. Prostasin displays
trypsin-like enzymatic activities by hydrolyzing peptidyl fluorogenic substrates such as D-Pro-Phe-Arg-AMC. This trypsinlike enzymatic activity can be inhibited by aprotinin, antipain,
leupeptin, and benzamidine. Prostasin is present at high levels
in normal human semen (8.61 ⫾ 0.42 g/ml) and in the prostate gland (143.7 ⫾ 15.9 ng/mg). Lower amounts of prostasin
can also be detected in other tissues. In the prostate gland, the
prostasin protein is present in the epithelial cells as well as in
the secretion inside the lumen. The full-length human prosta-
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in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
储 To whom correspondence should be addressed: Dept. of Molecular
Biology and Microbiology, University of Central Florida, 4000 Central
Florida Blvd., Orlando, FL 32816-2360. Tel.: 407-823-6122; Fax: 407823-3095; E-mail: kxchai@mail.ucf.edu.
1
The abbreviations used are: PAGE, polyacrylamide gel electrophoresis; GPI, glycosylphosphatidylinositol; PBP, prostasin-binding
protein; r-hPro, recombinant human prostasin; PBS, phosphate-buffered saline; MES, 4-morpholineethanesulfonic acid; PI-PLC, phosphatidylinositol-specific phospholipase C; ER, endoplasmic reticulum;
mPBP, mouse prostasin-binding protein; AMC, 7-amino-4-methylcoumarin; AFC, 7-amino-4-trifluoromethylcoumarin.

sin mRNA has been deduced (2). The predicted mature prostasin peptide sequence has a potential carboxyl-terminal hydrophobic membrane anchorage domain followed by a short
cytoplasmic tail. The translated amino acid residue sequence of
prostasin is similar to those of human prostase, testisin,
plasma kallikrein, coagulation factor XI, hepsin, plasminogen,
and acrosin (2– 4). A membrane-bound Xenopus kidney epithelial cell sodium channel-activating protease (CAP1) was found
highly homologous to human prostasin, sharing 53% sequence
identity at the amino acid level (5). Recently, the mouse counterpart of CAP1, mCAP1, has been cloned from a cortical collecting duct cell line (6). mCAP1 shares 77% amino acid sequence identity with human prostasin.
Serine proteases play important roles in a diverse range of
the body’s normal physiological processes, and they are implicated in various pathological processes such as cardiovascular
disorders and cancers (7). The prostate produces a number of
serine proteases such as prostate-specific antigen (8), human
glandular kallikrein (9), and the most recently discovered
prostase (3). Some of these serine proteases are suspected to
affect fertility or semen liquefaction (10), and others are implicated in normal prostate development or prostatic diseases
(11–14). For example, both prostate-specific antigen and human glandular kallikrein have become important diagnostic
and prognostic markers for prostate cancer. Serine proteases
are usually regulated at the post-translational level in addition
to the transcriptional regulation at their gene level. The body’s
own strategy of regulating the serine proteases is to bind the
serine proteases with a protein inhibitor such as the inhibitors
of the serpin class (15). These serpin-serine protease pairs are
highly specific with regard to the two molecules involved; examples include ␣1-antitrypsin and elastase (15), kallistatin and
kallikrein (16, 17), ␣1-antichymotrypsin and prostate-specific
antigen (18). The mechanism of serpin inhibition of serine
proteases involves the formation of a covalently linked complex
at a 1:1 stoichiometry (19). Such a complex exhibits resistance
to treatment with SDS or boiling (16, 17).
The physiological functions of prostasin are not fully understood. In a recent study (20) we showed that prostasin expression is significantly down-regulated in high grade prostate
tumors and is lost in highly invasive human and mouse prostate cancer cell lines. Transfection of two human prostate cancer cell lines DU-145 and PC-3 with human prostasin cDNA
reduced in vitro invasiveness of the cells, suggesting an invasion suppressor role for prostasin. This anti-invasion activity is
apparently conferred by the cellular prostasin but not the secreted prostasin. In the present study, we determined that
prostasin is a GPI-anchored membrane protein in addition to
being a secreted protease. The subcellular localization of prostasin was investigated in cells expressing native or recombi-
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A recombinant human prostasin serine protease was
expressed in several human cell lines. Subcellular fractionation showed that this serine protease is synthesized as a membrane-bound protein while a free-form
prostasin is secreted into the culture medium. Prostasin
was identified in nuclear and membrane fractions.
Membrane-bound prostasin can be released by phosphatidylinositol-specific phospholipase C treatment, or
labeled by [3H]ethanolamine, indicating a glycosylphosphatidylinositol anchorage. A prostasin-binding protein
was identified in mouse and human seminal vesicle
fluid. Both the secreted and the membrane-bound prostasin were able to form a covalently linked 82-kDa complex when incubated with seminal vesicle fluid. The
complex formation between prostasin and the prostasin-binding protein was inhibited by a prostasin antibody, heparin, and serine protease inhibitors. Prostasin’s serine protease activity was inhibited when bound
to the prostasin-binding protein in mouse seminal vesicle fluid. This study indicates that prostasin is an active
serine protease in its membrane-bound form.

GPI-anchored Prostasin
nant prostasin. We have also identified a prostasin-binding
protein (PBP), a potentially serpin class serine protease inhibitor specific for prostasin. We further demonstrated that the
membrane-bound prostasin is an active serine protease. These
results will provide structural and regulatory information for
further investigation of the functions of prostasin in normal
prostate development, prostatic diseases, as well as reproductive biology.
EXPERIMENTAL PROCEDURES

amounts of 1 M Tris, combined, concentrated with Centricon-10 concentrators (Amicon Inc., Beverly, MA), and stored at ⫺20 °C before use in
other assays.
Preparation of a Polyclonal Antiserum against Recombinant Prostasin—250 g of the purified r-hPro in 0.5 ml of phosphate-buffered saline
(PBS, pH 7.4) was emulsified with an equal volume of complete
Freund’s adjuvant (Sigma) and was injected subcutaneously into a
1.5-kg female New Zealand White rabbit (Charles River Laboratories,
Wilmington, MA). Booster injections with 100 g of r-hPro (emulsified
with incomplete Freund’s adjuvant, Sigma) were performed three times
at 3-week intervals. Preimmune rabbit serum was collected before the
initial immunization.
Immunocytochemistry—The PC-3/Pro or LNCaP cells were seeded on
glass coverslips (Fisher Scientific) at a density of 5 ⫻ 104/coverslip and
grown for 24 –36 h prior to a double immunostaining. Briefly, cells were
rinsed three times in 1 ⫻ PBS, fixed in 4% paraformaldehyde, and
permeablized with 0.18% Triton X-100 in PBS for 10 min. After blocking
in 10% normal goat serum (Life Technologies, Inc.) in 1 ⫻ PBS, cells
were incubated with the primary antibodies for 45 min, washed, incubated with the appropriate secondary antibodies at room temperature
for 30 min, and then washed three times for 10 min each in 1 ⫻ PBS. A
rabbit polyclonal antibody against prostasin was used at a dilution of
1:100. A monoclonal antibody against poly(ADP-ribose) polymerase was
used as a nuclear specific marker at a dilution of 1:75. A goat anti-rabbit
IgG conjugated with fluorescein (1:50, Life Technologies, Inc.) and a
goat anti-mouse IgG conjugated with Cy3 (1:800, Jackson ImmunoResearch, West Grove, PA) were used as the secondary antibodies. The
coverslips were mounted with Gel/Mount (Fisher Scientific) and analyzed on a Carl Zeiss LSM510 laser scanning microscope.
Subcellular Fractionation and Differential Extraction—Subcellular
fractionation was performed as described in Krajewski et al. (21) and
Pemberton et al. (22). Briefly, confluent cells in 4 ⫻ 150-cm2 flasks
(estimated 5–10 ⫻ 107 cells/total) were washed three times with 1 ⫻
PBS and removed by mechanical force for the 293/Pro cells or trypsin
treatment (0.25% with 1 mM EDTA) for the PC-3/Pro and LNCaP cells.
The cells were resuspended in 7 ml of cold MES buffer (17 mM at pH 7.4,
2.5 mM EDTA, and 250 mM sucrose) containing protease inhibitors (1
mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 2 g/ml leupeptin, and 2 g/ml antipain). The following steps were performed at 4 °C.
Cell suspension was homogenized with a Dounce homogenizer for 60
strokes followed by centrifugation twice at 500 ⫻ g for 10 min, resulting
in the crude nuclear fraction in the pellet. The supernatant was centrifuged twice at 10,000 ⫻ g for 15 min, resulting in the heavy membrane
fraction in the pellet containing mitochondria, lysosomes, and peroxisomes. The supernatant from the 10,000 ⫻ g centrifugation was subjected to an ultracentrifugation at 100,000 ⫻ g for 60 min, resulting in
a light membrane fraction in the pellet containing the plasma membrane, microsomes, and endoplasmic reticula. The supernatant from
the final centrifugation contains soluble or cytosolic proteins. The pellets from each centrifugation were washed with 2 ⫻ 10 ml of MES to
eliminate carryovers.
Differential extraction of membrane fractions was carried out according to Pei et al. (23). Briefly, pellet/membrane fractions were divided
equally into three portions and were extracted with 1% Triton X-114 in
Tris buffer (10 mM Tris-HCl, pH 7.5) or high salt (350 mM NaCl in Tris
buffer), or alkali (50 mM glycine/NaOH, pH 11.0) for 1 h on ice. The
samples were centrifuged at 100,000 ⫻ g for 30 min. The resulting
pellet was dissolved in 1 ⫻ SDS sample buffer for gel electrophoresis.
The supernatant was subjected to a trichloroacetic acid precipitation to
recover proteins for gel electrophoresis.
Detergent Phase Separation and Phosphatidylinositol-specific Phospholipase C (PI-PLC) Treatment—The procedure was adapted from
those described by Bordier (24) and Rosenberg (25). Briefly, cells (5 ⫻
106) were lysed in 1 ml of ice-cold TBS (10 mM Tris-HCl at pH 7.5, 150
mM NaCl, 1 mM EDTA) containing 1% Triton X-114 (Sigma) and protease inhibitors for 2 h with gentle shaking at 4 °C. The lysate was then
centrifuged at 14,000 rpm for 30 min. The supernatant (500 l, or
700 – 800 g of total protein) was overlaid onto a 300-l sucrose cushion
(6% w/v sucrose in TBS containing 0.06% Triton X-114). The solution
was incubated at 37 °C for 3 min and centrifuged at 300 ⫻ g for 3 min
at room temperature to separate the detergent phase (pellet) and the
aqueous phase. The aqueous phase was removed and extracted further
with 0.5% Triton X-114 and 2% Triton X-114. The aqueous phase after
the final centrifugation contains the soluble proteins. The detergent
phase (pellet) from the first centrifugation was resuspended in 500 l of
ice-cold TBS, incubated at 37 °C for 3 min, and centrifuged at 300 ⫻ g
for 3 min at room temperature to ensure the purity of the detergent
phase.
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Cell Lines and Plasmid DNA Transfection—A human embryonic
kidney epithelial cell line, 293-EBNA (Invitrogen, Carlsbad, CA), was
maintained in Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum. Human prostate cancer cell lines LNCaP,
DU-145, and PC-3 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The LNCaP and the DU-145 cells
were maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum and 1 mM sodium pyruvate; the PC-3 cells were maintained in F-12K medium supplemented with 10% fetal bovine serum.
All cells were kept at 37 °C with 5% CO2. All tissue culture media, sera,
and supplements were purchased from Life Technologies, Inc.
A full-length human prostasin cDNA of 1,896 base pairs (including a
209-base pair 5⬘-untranslated region, 1,032 base pairs of the coding
region, and a 655-base pair 3⬘-untranslated region) was generated by
means of reverse transcription-polymerase chain reaction with the following two primers, 5⬘-AGA CGG TGC TGG TGA CTC GT-3⬘ and
5⬘-TGT GCT CAA ACA TTT TAA TC-3⬘, using the total RNA of LNCaP
cells as template (2). The amplified cDNA was cloned into a mammalian
expression vector, pREP-8 (Invitrogen), at its polylinker site. Transfection of the prostasin cDNA plasmid into 293-EBNA cells was carried out
using electroporation. The electroporated cells were then subcultured
for selection of transfectants (293/Pro) using 5 mM histidinol (Sigma) in
the culture medium for 2 weeks. The pREP-8 vector plasmid was
transfected into 293-EBNA cells and subjected to histidinol selection to
establish the control cells (293/Vec).
The DU-145 and the PC-3 cells, which do not express prostasin (20),
were also transfected using plasmids containing the full-length human
prostasin cDNA. The methods for plasmid engineering and establishment of transfectants that express human prostasin have been described previously (20). The resulting cell lines that express human
prostasin were designated DU-145/Pro and PC-3/Pro.
SDS-PAGE and Western Blot Analysis—These procedures were carried out for all experiments unless stated otherwise. Samples were
suspended in 1 ⫻ SDS sample buffer (62.5 mM Tris-HCl at pH 6.8, 2%
v/v glycerol, 2% w/v SDS, and 2% ␤-mercaptoethanol), boiled for 5 min,
and resolved in a 10% polyacrylamide gel. The resolved proteins were
then transferred to a nitrocellulose membrane. The membrane was
stained with India ink for 15 min (1:1,000 in TBS-T: 20 mM Tris at pH
7.6 containing 0.137 M NaCl and 0.1% Tween 20), blocked in 5% non-fat
milk for 1 h, and incubated with the primary antibody for 30 min in a
tray or a Surf-blot apparatus (Idea Scientific, Inc., Minneapolis). After
washing, the membrane was incubated with a secondary antibody conjugated with horseradish peroxidase (Sigma, used at a 1:10,000 dilution) for 30 min. Signals were detected using ECL (enhanced chemiluminescence) with WestPico reagents (Pierce) following the supplier’s
protocol. The membrane was then exposed to Kodak x-ray film. The
primary antibodies used were as follows: polyclonal antibodies against
prostasin (recombinant or native, used at 1:1,000), a monoclonal antibody against ␤1-integrin (used at 1:1,000), and a monoclonal antibody
against poly(ADP-ribose) polymerase (used at 1:500). Antibodies
against ␤1-integrin and poly(ADP-ribose) polymerase were from BD
Transduction Laboratories (San Diego).
Purification of Recombinant Human Prostasin—The 293/Pro cells
were grown to a confluent monolayer in Dulbecco’s modified Eagle’s
medium and 10% fetal bovine serum containing 5 mM histidinol. Cells
were then placed in Opti-MEM I serum-free medium (Life Technologies,
Inc.) for 72 h before collection of the conditioned medium. The collected
medium was tested for recombinant prostasin (r-hPro) by Western blot
analysis using a prostasin-specific antibody (1). For purification of the
secreted prostasin, the serum-free medium was centrifuged at 10,000
rpm for 20 min to remove dead cells or debris and then passed through
an aprotinin-agarose column (1.5 ⫻ 20 cm, Sigma) equilibrated with 25
mM Tris-HCl at pH 7.6 at a flow rate of 25 ml/h. After extensive washing
to remove any unbound proteins, the bound prostasin was eluted with
0.1 M glycine (pH 3.0) containing 0.1 M NaCl at a flow rate of 60 ml/h.
The eluted prostasin was immediately neutralized with appropriate
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FIG. 1. SDS-PAGE and Western blot analysis. Recombinant human prostasin purified from serum-free conditioned medium of the
293/Pro cells was analyzed by 10% SDS-PAGE under reducing conditions. The purified recombinant prostasin (3 g) migrated at 40 kDa
(left panel, r-hPro) and is recognized by an antibody made against the
purified recombinant prostasin (IB: r-Pro Ab, lane 1) as well as a
prostasin-specific antibody made against purified native prostasin (IB:
n-Pro Ab, lane 1, Ref. 1). The quantity of purified prostasin in lanes 1 is
0.5 g. Samples from the 293/Pro cell lysate (lanes 2, 20 g), 293/Vec
(lanes 3, 20 g) cell lysate, and human semen (lanes 4, 30 g) were
immunoblotted with r-Pro antibody (upper right panel, 1:1,000 dilution)
and n-Pro antibody (lower right panel, 1:1,000 dilution). Both antibodies recognize the recombinant prostasin as well as the native prostasin
but do not have cross-reactivity with 293/Vec proteins.

RESULTS

Expression and Purification of Recombinant Human Prostasin—Serum-free conditioned medium from 293/Pro cell culture
was prepared and passed through an aprotinin-agarose column
for a one-step affinity-chromatographic purification of the recombinant prostasin as described under “Experimental Procedures” (see also Ref. 1). A Coomassie Blue staining of the
purified recombinant prostasin is shown in Fig. 1, left panel
(r-hPro). The r-hPro migrates at 40 kDa on an SDS-PAGE
under reducing conditions. Because of glycosylation of the prostasin molecule (1, 2), it appeared as a rather diffused band on
the gel. We prepared a polyclonal antibody (r-Pro Ab) using the
purified r-hPro as an antigen. The r-Pro antibody recognized
the purified recombinant prostasin (secreted form), the recombinant prostasin in 293/Pro total cell lysate (nonsecreted form),
and the native prostasin in ejaculated human semen (obtained
from healthy volunteers, Ref. 1) (Fig. 1, upper right panel, lanes
1, 2, and 4). The prostasin protein in the same set of samples
was also recognized by a prostasin-specific antibody referenced
previously (1) (Fig. 1, lower right panel). Neither antibody
cross-reacts with any nonspecific protein in the control 293/Vec
total cell lysate (Fig. 1, right panel, lanes 3). The results indicate that the polyclonal antibody against the recombinant prostasin is specific to prostasin and that the recombinant prostasin prepared using the amplified cDNA has an immunological
reactivity similar to that of the native prostasin. The antibody
against the recombinant prostasin was used in the ensuing
assays conducted in this study.
Recombinant Prostasin Is a Membrane-bound Protein—A hydropathy plot of the translated prostasin amino acid sequence
indicated that the prostasin polypeptide has a potential membrane-anchorage domain at the carboxyl terminus (2). To confirm the presence of a potentially membrane-anchored form of
the prostasin protein, the 293/Pro cells were subjected to subcellular fractionation by differential centrifugation. Fig. 2
shows that prostasin was present in the crude nuclear fraction
(P1, 500-g pellet), heavy membranes (P2, 10,000-g pellet), and
light membranes (P3, 100,000-g pellet), as determined by Western blot analysis. Prostasin was also detected in the cytosol (S).
The purified r-hPro was used as positive control. Equal
amounts of total protein (30 g) from each membrane fraction
and the cytosol were applied in each lane.
To show that the membrane-anchored prostasin is not a
peculiarity in the 293 cells, we performed similar subcellular
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The detergent phase was resuspended in 100 l of ice-cold TBS. 10 l
of the resuspended detergent phase was subjected to PI-PLC (Sigma)
digestion at 37 °C for 1 h with gentle shaking in a total volume of 100
l of reaction buffer (10 mM Tris-HCl at pH 7.5, 144 mM NaCl). 100 l
of ice-cold TBS containing 2% Triton X-114 was then added to the
digestion mixture and subjected to phase separation as described above.
At the final step, both the aqueous and detergent phases were precipitated with 6% w/v trichloroacetic acid and 0.013% sodium deoxycholate. The precipitates were resuspended in 30 l of 1 ⫻ SDS sample
buffer, neutralized with ammonium hydroxide (microliter amounts),
boiled, and subjected to SDS-PAGE and Western blot analysis.
Human prostates removed by radical prostatectomy performed at
Orlando Regional Medical Center (Orlando, FL) were sectioned with a
cryostat at 20-m thickness. 80 sections were collected and rinsed with
PBS twice to remove prostatic fluid. The washed prostate sections were
lysed in 1 ml of TBS containing 1% Triton X-114 at 4 °C overnight with
rocking. The lysed prostate tissues were centrifuged and subjected to
the same phase separation and PI-PLC treatment procedures as described above. Several representative prostate sections (7 m) cut at
intervals of the 80 20-m sections were subjected to standard hematoxylin and eosin staining for confirmation of benign prostate morphology. The use of human tissues was approved by the Institutional Review
Boards of Orlando Regional Medical Center and the University of
Central Florida.
[3H]Ethanolamine Labeling, Immunoprecipitation, and Fluorography—PC-3/Pro (3 ⫻ 105) or LNCaP (1 ⫻ 106) cells were seeded in a
35-mm dish in 1 ml of Opti-MEM I serum-free medium. The next day,
[1-3H]ethan-1-ol-2-amine hydrochloride (37 MBq, 1 mCi/ml, and 30.0
Ci/mmol, Amersham Pharmacia Biotech) was added to the culture
medium at a concentration of 100 Ci/ml, and the cells were cultured
for another 24 h. Cells were washed once with PBS and lysed in 0.5 ml
of RIPA buffer (PBS at pH 7.4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors at 4 °C for 1 h. The
lysate was centrifuged at 14,000 rpm for 30 min to remove insoluble
material. The supernatant was subjected to immunoprecipitation with
2 g/ml anti-prostasin IgG (purified using Econo-Pac protein A cartridge, Bio-Rad) and protein A-Sepharose beads (Sigma) at 4 °C overnight. The beads were washed with RIPA buffer three times, resuspended in 2 ⫻ SDS sample buffer with ␤-mercaptoethanol, boiled, and
analyzed by SDS-PAGE. The gel was fixed in a solution of 2-propanol:
water:acetic acid (12.5: 32.5: 5) for 30 min and soaked in Amplify
fluorographic reagent (Amersham Pharmacia Biotech) for another 30
min. The gel was dried, and 3H-labeled molecules were detected by
exposure to an x-ray film with an intensifying screen at ⫺80 °C for
14 days.
Prostasin Binding Assay—Seminal vesicle fluid was expressed from
one pair of mouse seminal vesicles (C57BL/6 mouse, Harlan, Indianapolis) and mixed with 1 ml of 25 mM Tris-HCl, pH 7.6, and centrifuged at
14,000 rpm at 4 °C for 30 min. 5 l of the supernatant (50 g of total
protein) was incubated with either 0.5 g of the purified recombinant
human prostasin or subcellular fractions of 293/Pro and PC-3/Pro cells
(prepared in the absence of serine protease inhibitors) at 37 °C for 60
min, or for various time periods for a time course study. The binding
reaction was stopped by the addition of SDS sample buffer and heating
at 100 °C for 5 min. Mouse tissues were homogenized in PBS (1 g of
tissue/5 ml) and centrifuged in a microcentrifuge at 14,000 rpm for 30
min at 4 °C. 40 g of total protein for each tissue extract was used in the
binding assay. 1 l of human or mouse plasma was also subjected to
prostasin binding assay. The use of animals was approved by the
IACUC of the University of Central Florida. Human seminal vesicles
were obtained from radical prostatectomy performed at Orlando Regional Medical Center. No seminal vesicle metastasis from prostate
cancer was found according to the pathology report. Human seminal
vesicle fluid was diluted with PBS at a ratio of 1:2, mixed by vortex, and
spun. 10 l of the diluted fluid was incubated with 0.5 g of purified
prostasin at 37 °C for 60 min.
Membrane Overlay Zymography—The membrane overlay zymography was carried out using the protocols of Enzyme System Product
(Livermore, CA) and Beals et al. (26). Briefly, samples were first resolved in a 10% polyacrylamide gel without SDS or ␤-mercaptoethanol.
After electrophoresis, the gel was equilibrated in a reaction buffer (50
mM Tris-HCl, pH 9.0) for 15 min. Pre-wet acetate-cellulose membrane
impregnated with the prostasin substrate D-Pro-Phe-Arg-AFC (Enzyme
System Product) was then carefully laid over the gel without entrapping air bubbles. The membrane-overlaid gel was placed in a moist
chamber at 37 °C for 3–5 h. The reaction was monitored using an
ultraviolet lamp and photographed.
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FIG. 2. Analysis of prostasin in 293/Pro cell fractions. The cells
were fractionated through differential centrifugation. An equal amount
of protein (30 g) from each centrifugation step was resolved by 10%
SDS-PAGE followed by immunoblotting with a prostasin-specific polyclonal antibody (1:1,000 dilution). Prostasin (40 kDa) is detected in the
nuclear fraction (P1), heavy membrane fraction (P2, including mitochondria, lysosomes, and peroxisomes), light membrane fraction (P3,
including plasma membrane, microsomes, and endoplasmic reticula) as
well as the cytosol (S) of 293/Pro. Purified r-hPro (0.5 g) was used as
a positive control.

FIG. 3. Analysis of prostasin in prostate cancer cell lines. Panel
A, Western blot analysis of membrane-bound prostasin in PC-3/Pro and
LNCaP cells. The experimental procedures were the same as described
in Fig. 2. Prostasin (40 kDa) is detected in the nuclear fraction (P1),
heavy membrane fraction (P2), light membrane fraction (P3), but not in
the cytosol (S) of PC-3/Pro. In LNCaP cell fractions, prostasin is detected only in P3. Antibodies against a nuclear protein, the poly(ADPribose) polymerase (PARP, 1:500, or 0.5 ng/ml), and a plasma membrane protein, ␤1-integrin (1:1,000, or 0.25 ng/ml), were used as
fractionation markers. Panel B, confocal microscopic localization of
prostasin. The PC-3/Pro and LNCaP cells were fixed, permeablized, and
subjected to a double immunostaining. One focal plane for each cell type
is presented to show prostasin signals (green). Prostasin is detected
primarily at the nuclear-ER-Golgi complex as well as punctate regions
in the PC-3/Pro cell. In the LNCaP cells, no punctate prostasin can be
seen. The nuclear marker protein poly(ADP-ribose) polymerase (red) is
seen in both cell types. A merge image for either cell type is presented
to the right. The images were taken after subtracting background
signal on a preimmune serum-stained control coverslip. Magnification,
⫻ 400. The antibody dilution ratios are: anti-prostasin, 1:100; antipoly(ADP-ribose) polymerase, 1:75 (or 3.3 ng/ml); goat anti-rabbit IgG
conjugated with fluorescein isothiocyanate, 1:50; and goat anti-mouse
IgG-Cy3, 1:800.

FIG. 4. Recombinant prostasin is a true membrane-bound protein. Approximately 80 –100 g of total protein of each membrane
fraction of PC-3/Pro cells (as described in legend to Fig. 3A) was subjected to detergent (TX), high salt (HiS), or alkali (Alk) treatment
followed by centrifugation to separate the supernatant and the pellet
for SDS-PAGE and Western blot analysis. Prostasin in all fractions can
only be released from the membrane (pellet) to the supernatant (soluble
protein) by the detergent treatment but not high salt or alkali
treatment.

293/Pro cells is associated with the membrane, which was
retained in the detergent phase. The size difference between
the soluble and the membrane-bound prostasin may be attributed to the GPI moiety that is linked to prostasin (Fig. 5, lanes
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fractionation analysis on prostasin cDNA-transfected human
prostate cancer cell line PC-3 (PC-3/Pro) and the human prostate cancer cell line LNCaP, which expresses endogenous prostasin (2, 20). As shown in Fig. 3A, prostasin is detected in P1,
P2, and P3 fractions, but not in the cytosol (S) of PC-3/Pro. In
the LNCaP cells, endogenously expressed prostasin is detected
only in the P3 fraction. The membrane fractions from PC-3/Pro
cells were then immunoblotted with a monoclonal antibody
against a nuclear protein poly(ADP-ribose) polymerase or a
monoclonal antibody against a plasma membrane-bound protein ␤1-integrin to ensure the purity of each fraction. The
results showed that the prostasin protein exists in a membrane-bound form in all cell lines tested. The cells transfected
with the vector DNA alone (293/Vec and PC-3/Vec) were subjected to the same fractionation procedures followed by SDSPAGE/Western blot analysis. No prostasin was detected (data
not shown). We further subjected PC-3/Pro and LNCaP cells to
a double immunostaining and analyzed the subcellular localization of prostasin using confocal microscopy. The confocal
microscopic analysis of PC-3/Pro cells localized prostasin
(green) to the ER-Golgi complex (Fig. 3B), consistent with the
cell fractionation results shown in Fig. 3A. Because the nuclear
membrane is practically a prominent component of the ER (27),
it is not surprising that this portion of prostasin appeared in
the P1 fraction. The LNCaP cells, however, did not show punctate or nuclear-ER-Golgi complex staining, again, consistent
with the cell fractionation results shown in Fig. 3A.
To test if prostasin is truly a membrane-anchored protein
rather than a membrane-associated protein, we subjected the
P1, P2, and P3 fractions of the PC-3/Pro cells to treatment with
a detergent, high salt, or alkali. As shown in Fig. 4, membranebound prostasin (pellet) was released into the supernatant only
by the detergent treatment but not the high salt or alkali
treatment. The detergent released prostasin and the membrane-bound prostasin had similar molecular weight. The results indicated that prostasin is a true membrane-anchored
protein.
Membrane Prostasin Is GPI-anchored—A comparison of the
potential carboxyl-terminal membrane-anchorage domain of
prostasin (2) with GPI-anchored proteins (28) predicts a GPI
linkage for prostasin as well (data not shown). Such a linkage
may be susceptible to cleavage by PI-PLC, GPI-specific phospholipase D, or nitrous acid (25). In our studies, we first chose
PI-PLC to test if prostasin is a GPI-anchored membrane protein. The 293/Pro cells were lysed in TBS containing 1% Triton
X-114. After phase separation, the aqueous phase (Fig. 5, lane
1, 30 g of total protein) and the detergent phase (lane 2, 3 g
of total protein) were analyzed by Western blot using the prostasin-specific antibody. The majority of the prostasin protein in
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1 and 2). The detergent phase was then subjected to PI-PLC
digestion at various enzyme concentrations followed by a second phase separation. In Fig. 5, lanes 3–5 represent samples of
the aqueous phases after PI-PLC digestion. The PI-PLC treatment released prostasin from the detergent phase in a dose-dependent manner (lane 3, 0.25 unit; lane 4, 0.125 unit, and lane
5, 0 units). The PI-PLC-released prostasin and the soluble
prostasin are similar in molecular mass as shown in Fig. 5. The
results support a GPI-anchoring mechanism for the membrane-bound prostasin.
One question that remained unclear was whether the native
prostasin in the prostate tissue epithelial cells is membranebound by GPI anchorage as well. We selected a panel of prostate cancer cell lines and 293/Pro cells that express either
recombinant or endogenous prostasin, and normal human prostate tissues in our next experiment. Cell lines that express
recombinant prostasin were 293/Pro, PC-3/Pro, and DU-145/
Pro. The human prostate cancer cell line LNCaP and normal
human prostate tissues were used for testing native cellular
prostasin. All samples (300 g of total protein as the starting
quantity) were subjected to detergent phase separation before
and after PI-PLC digestion as described under “Experimental
Procedures.” PC-3 transfected with a vector plasmid (PC-3/Vec)
was used as negative control. The results are presented in Fig.
6A. Without PI-PLC treatment, both the recombinant and native prostasin are mainly membrane-anchored (found in the
detergent phase). Soluble prostasin is detected in 293/Pro and
prostate tissues. After PI-PLC treatment, the membrane-anchored prostasin is released into the soluble fraction from 293/
Pro, PC-3/Pro, and prostate tissues, but not from DU-145/Pro
and LNCaP. The results indicated that the native prostasin in
normal human prostate tissue is also GPI-anchored. The membrane-bound prostasin in DU-145/Pro and LNCaP is resistant
to PI-PLC digestion. We further tested if prostasin can be
labeled biosynthetically with [3H]ethanolamine, which is specifically incorporated in the GPI unit of GPI-anchored proteins
(29). We chose the PC-3/Pro (expressing recombinant prostasin) and LNCaP (expressing native prostasin) cells for [3H]ethanolamine biosynthetic labeling. As shown in Fig. 6B, [3H]ethanolamine was incorporated into either recombinant or native
prostasin, demonstrating that both are truly GPI-anchored.

FIG. 6. Prostasin is a GPI-anchored membrane protein. Panel
A, detergent phase separation and PI-PLC treatment. Human prostate
tissues and cell lines that express either endogenous prostasin (LNCaP)
or recombinant prostasin (293/Pro, PC-3/Pro, and DU-145/Pro) were
subjected to detergent phase separation/PI-PLC digestion followed by
prostasin immunoblotting (300 g of total protein was used for each
sample as the starting quantity). Both the recombinant and native
prostasin are mainly membrane-anchored (pre-PLC, detergent phase or
D). Soluble prostasin is detected in 293/Pro and prostate tissues (prePLC, soluble phase or S). After PI-PLC treatment, the membraneanchored prostasin is released into the soluble fraction from 293/Pro,
PC-3/Pro, and prostate tissues (post-PLC, S) but not from DU-145/Pro
and LNCaP (post-PLC, D). The PC-3/Vec cells showed negative results
in all fractions tested. Because of a high level prostasin expression in
the 293/Pro cells, a portion of prostasin remained in the detergent phase
after PI-PLC digestion. Panel B, incorporation of [3H]ethanolamine into
prostasin. PC-3/Pro or LNCaP cells were incubated with 100 Ci of
[3H]ethanolamine in 1 ml of Opti-MEM I serum-free medium for 24 h in
5% CO2 at 37 °C. The cell lysates were subjected to immunoprecipitation using the prostasin antibody (purified IgG fraction, 2 g/ml) and
protein A-Sepharose beads as described under “Experimental Procedures.” After SDS-PAGE separation of the samples, the labeled protein
was detected by fluorography using Amplify fluorographic reagent and
exposure to an x-ray film at ⫺80 °C with an intensifying screen for
14 days.

Identification of a Prostasin-binding Protein—An incubation
of the purified r-hPro with mouse or human seminal vesicle
fluid yielded a higher molecular weight form of prostasin-containing band as analyzed by SDS-PAGE and immunoblotting.
The result presented in Fig. 7A indicated that the purified
r-hPro formed an 82-kDa complex with a mouse seminal vesicle
protein (named as the mouse prostasin-binding protein, or
mPBP). The complex was apparently covalently linked and not
via a disulfide bond because it was SDS- and heat-stable and
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FIG. 5. Detergent phase separation of 293/Pro cells and phospholipase C treatment. The 293/Pro cells were lysed in TBS containing 1% Triton X-114 and subjected to phase separation (700 – 800 g of
total protein as the starting quantity). The detergent phase containing
membrane-associated proteins (equivalent to 1/10 of the total starting
membrane-associated proteins) was further treated with PI-PLC followed by additional phase separation. The soluble proteins (lane 1, 30
g) and the detergent phase proteins (lane 2, 3 g) before PI-PLC
treatment and the soluble proteins extracted from the detergent phase
after PI-PLC treatment were subjected to SDS-PAGE and Western blot
analysis using a prostasin-specific antibody. The membrane-bound
prostasin is released from the membrane after PI-PLC digestion as it
was detected in the post-PLC soluble phase. The amounts of PI-PLC
used in the reactions are: lane 3, 0.25 unit; lane 4, 0.125 unit; and lane
5, 0 unit in a total reaction volume of 100 l. The results indicate that
prostasin is anchored to membrane via GPI. The size difference between the membrane-bound prostasin and the soluble prostasin (lanes
1 and 2) may be attributed to the GPI moiety that is linked to prostasin.
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FIG. 7. Complex formation between prostasin and its binding
protein. Panel A, 0.5 g of purified recombinant prostasin was incubated with mouse seminal vesicle fluid at 37 °C for various time periods
as indicated. The samples were subjected to SDS-PAGE under reducing
conditions followed by immunoblotting with a prostasin-specific antibody. Prostasin forms an 82-kDa complex (upper arrow) with mPBP in
mouse seminal vesicle fluid. The complex formation can be detected as
early as 1 min postincubation. Excess unbound prostasin is indicated by
the lower arrow. Prostasin alone without incubation with mouse seminal vesicle fluid is labeled as 0 min. Panel B, various mouse tissue
extracts were analyzed in a prostasin binding assay and prostasin
immunoblotting as described. SVF, mouse seminal vesicle fluid; Coag.
gl., coagulating gland; Vas def., vas deferens; Adrenal gl., adrenal
gland; Salivary gl., salivary glands. Panel C, 0.5 g of purified recombinant prostasin was incubated with human seminal vesicle fluid at
37 °C for 60 min. Similarly, prostasin forms an 82-kDa complex with the
hPBP in human seminal vesicle fluid (lane 2), and the complex formation
was inhibited by 1 unit of heparin (lane 3). Purified recombinant prostasin
alone was used as a control (lane 1). Panel D, human or mouse plasma was
tested in a prostasin binding assay. HUK, human urinary (tissue) kallikrein (0.5 g); Pro, purified recombinant prostasin (0.5 g); SVF,
mouse seminal vesicle fluid (5 l); MP, mouse plasma (1 l); HP, human
plasma (1 l). Lanes 1–3, probed with prostasin antibody (1:1,000); lane
4, probed with a human kallikrein antibody (1:1,000).

resistant to ␤-mercaptoethanol. The complex formation was
detected at as early as 1 min postincubation with a t1/2 of ⬃5
min and reached a plateau at ⬃20 min. Densitometry meas-

urements of the complex bands in different lanes were performed using the LabWork 3.0 software (Ultra-Violet Products,
Upland, CA) (data not shown). Mouse plasma and various
tissue extracts including the prostate, coagulating gland, testis, epididymis, vas deferens, adrenal gland, pituitary, thymus,
liver, lung, kidney, spleen, heart, brain, uterus, pancreas, and
salivary glands were subjected to the same prostasin-binding
assay procedures. No SDS- and heat-stable complex was detected under the same experimental conditions (Fig. 7B). A
PBP in human seminal vesicle fluid was also identified. As
shown in Fig. 7C, lane 2, a higher molecular mass complex (82
kDa) was detected after an incubation of r-hPro with the human seminal vesicle fluid. The complex formation between
prostasin and the human seminal vesicle PBP was inhibited by
heparin (Fig. 7C, lane 3). Incubation of mouse or human
plasma with r-hPro did not result in formation of any SDS- and
heat-stable complex (Fig. 7D, lane 1, mouse plasma; lane 3,
human plasma). In control assays, mouse plasma was incubated with prostasin for 30 min before seminal vesicle fluid was
added for another 30 min of incubation to demonstrate the
binding activity of the prostasin being tested in the presence of
plasma (Fig. 7D, lane 2). Or, human plasma was incubated
with purified human tissue kallikrein and subjected to a Western blot analysis using a human kallikrein-specific antibody
(30) (Fig. 7D, lane 4). The control binding assay showed a
92-kDa kallikrein-kallistatin complex as described previously
(16), demonstrating the quality of the human plasma being
tested.
The complex formation between prostasin and mPBP was
investigated further by incubating the purified r-hPro with
serine protease inhibitors (Fig. 8, lanes 2–5) or the prostasin
antibody (lanes 7 and 8) for 15 min at room temperature before
an incubation with mouse seminal vesicle fluid for another 60
min at 37 °C. Or, mouse seminal vesicle fluid was first incubated with heparin before the addition of prostasin (Fig. 8, lane
6). The complex formation between prostasin and mPBP was
inhibited by serine protease inhibitors such as aprotinin at
dosages of 1 g/ml and 5 g/ml, phenylmethylsulfonyl fluoride
at dosages of 1 mM and 5 mM, and prostasin antibody at 0.1 l
and 0.5 l. The amount of the complex was either reduced or
absent in the corresponding lanes of Fig. 8. Heparin (1 unit,
lane 6) inhibited complex formation. Complex formation between prostasin and mPBP without additional reagents was
used as the binding reaction control (Fig. 8, lane 1). The results
suggested that mPBP interacts with prostasin at the serine
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FIG. 8. Inhibition of complex formation between prostasin and
mPBP. 0.5 g of Purified recombinant prostasin was incubated with 5
l of mouse seminal vesicle fluid in the presence of aprotinin (lanes 2
and 3), phenylmethylsulfonyl fluoride (PMSF; lanes 4 and 5), heparin
(lane 6), prostasin antibody (lanes 7 and 8) at 37 °C for 1 h. All samples
were subjected to SDS-PAGE under reducing conditions followed by
immunoblotting with a prostasin-specific antibody. The complex formation (upper arrow) between prostasin and mPBP in mouse seminal
vesicle fluid is inhibited by aprotinin, phenylmethylsulfonyl fluoride,
heparin, and the antibody against prostasin. The asterisk (*) indicates
the IgG heavy chain and light chain recognized by the goat anti-rabbit
secondary antibody used in the Western blot analysis. Excess unbound
prostasin is indicated by the lower arrow. Complex formation between
r-hPro and mPBP in mouse seminal vesicle fluid without any other
reagent was used as positive control (lane 1).
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active site and that heparin may alter mPBP binding property.
The properties displayed by mPBP are shared by the serpin
class serine protease inhibitors. We have observed similar
properties for the serpin, kallistatin (16, 17). The predicated
molecular mass of PBP (mouse or human) is estimated at ⬃47
kDa, given the 40-kDa apparent molecular mass of prostasin
and considering the fact that serpin molecules lose a carboxylterminal fragment of ⬃5 kDa when complexed with a serine
protease (31).
mPBP Inhibits the Serine Protease Activity of Prostasin—We
performed a membrane overlay zymography analysis to test if
mPBP inhibits prostasin activity in vitro. The prostasin binding assay was carried out by incubating the purified r-hPro
with mouse seminal vesicle fluid in the absence of the serine
protease inhibitor aprotinin (Fig. 9, lane 3) or in the presence of
aprotinin (lane 4). Each sample was then divided into two equal
portions and subjected to a native PAGE analysis (i.e., SDS and
␤-mercaptoethanol were not included in the gel solution or the
samples, and the samples were not heated before loading)
followed by membrane overlay zymography (left panel) or Western blot analysis using the prostasin antibody (right panel).
Mouse seminal vesicle fluid proteins alone (Fig. 9, lane 1)
displayed no enzymatic activities toward the synthetic substrate D-Pro-Phe-Arg-AFC (left panel) nor cross-reactivity with
the prostasin antibody (right panel). The purified r-hPro alone
(lane 2) demonstrated enzymatic activity toward D-Pro-PheArg-AFC (left panel) and was recognized by the prostasin antibody (right panel). When prostasin formed a complex with
mPBP in the mouse seminal vesicle fluid, it no longer cleaves
D-Pro-Phe-Arg-AFC because no fluorescence is present at the
complex band location in lane 3 of the left panel, whereas the
complex is identified by the prostasin antibody as the upper
band in lane 3 of the right panel. The remaining unbound
prostasin yielded, expectedly, lesser fluorescence (left panel,
lower band in lane 3 compared with lane 2) and was recognized
by the prostasin antibody (right panel, lane 3). When the purified r-hPro was preincubated with the serine protease inhibitor
aprotinin before incubation with the mouse seminal vesicle
fluid, no complex was detected (right panel, lane 4). A reduced
level of fluorescence appeared at the prostasin band in lane 4 of

the left panel because of the presence of aprotinin. Because the
binding of aprotinin to prostasin was reversible while proteins
were being resolved in the gel, the inhibition of prostasin activity seen in lane 4 was not complete. The results suggested
that mPBP not only binds to prostasin at the serine active site
but also inhibits the serine protease activity of prostasin in
vitro. Two bands were observed in the prostasin alone sample
in the immunoblot (Fig. 9, right panel, lane 2), the differential
mobility may be caused by differential glycosylation (1). Aprotinin binding to prostasin changes the charge/mass ratio of the
protein; therefore, migration of the aprotinin-bound prostasin
in a native PAGE could change as well, potentially causing the
multiple banding pattern seen in lane 4 of the immunoblot
(Fig. 9, right panel).
Membrane Prostasin Binds to mPBP—To test if the membrane-bound prostasin has binding activity toward mPBP, the
293/Pro and PC-3/Pro cells were subjected to differential centrifugation as described under “Experimental Procedures” except that no protease inhibitors were added during membrane
fractionation. Immediately after centrifugation, an aliquot of
each membrane fraction (30 – 40 g of total protein) was incubated with an aliquot of mouse seminal vesicle fluid (5 l) at
37 °C for 1 h. The binding mixture was then analyzed by
Western blot analysis using a prostasin-specific antibody. In
Fig. 10, the left panel shows that the membrane-bound prostasin in 293/Pro cells (P2 and P3 fractions) formed an 82-kDa
complex when incubated with mouse seminal vesicle fluid. The
prostasin protein in the crude nuclear fraction (P1) and the
cytosol (S) did not form any detectable complex. The purified
r-hPro from the conditioned medium (i.e. the secreted prostasin)
was used as positive control for the binding assay. In Fig. 10,
right panel, we show that the membrane-bound prostasin in
PC-3/Pro cells also formed a complex with mPBP, and this reaction was inhibited by the serine protease inhibitor aprotinin.
DISCUSSION

The prostasin serine protease is predominantly synthesized
in the prostate in human (1). Recently our laboratory demonstrated that prostasin expression is significantly down-regulated in high grade prostate tumors and absent in invasive
human and mouse prostate cancer cell lines. We have also
shown, in an in vitro Matrigel invasion assay, that cellular
prostasin may be an invasion suppressor of prostate cancer
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FIG. 9. Membrane overlay zymography. Samples from a prostasin
binding assay were resolved on a 10% native acrylamide gel without
SDS/boiling or ␤-mercaptoethanol. The gel was then either overlaid
with a membrane impregnated with a prostasin substrate (D-Pro-PheArg-AFC) (left panel) or transferred for prostasin immunoblotting (right
panel). Lane 1, 5 l of mouse seminal vesicle fluid alone; lane 2, 0.5 g
of purified r-hPro alone; lane 3, mixture of r-hPro and mouse seminal
vesicle fluid; lane 4, same as lane 3 except r-hPro was preincubated with
5 g/ml aprotinin for 15 min before the addition of mouse seminal
vesicle fluid. The fluorogenic substrate impregnated in the membrane
was hydrolyzed by prostasin in the gel, and isoprostasin patterns in the
membrane appear as fluorescent bands. The results suggest that mPBP
not only binds to prostasin at the serine active site but also inhibits
prostasin’s serine protease activity in vitro.

FIG. 10. Membrane-bound prostasin forms a complex with
mPBP. Membrane fractions of 293/Pro and PC-3/Pro cells (30 – 40 g of
total protein) were incubated with 5 l of mouse seminal vesicle fluid at
37 °C for 1 h. Right panel, samples where indicated, were preincubated
with aprotinin before the addition of mouse seminal vesicle fluid. All
sample mixtures were analyzed on an SDS-PAGE under reducing conditions followed by prostasin immunoblotting. P1, nucleus fraction; P2,
heavy membranes; P3, light membranes; S, cytosolic proteins; and
r-hPro, purified recombinant prostasin. The membrane-bound prostasin in heavy or light membrane fractions formed a complex (upper
arrow) when incubated with mouse seminal vesicle fluid, whereas prostasin in P1 and cytosolic fractions showed no complex formation. r-hPro
was used as a positive control in the in vitro binding assay. Excess
unbound prostasin is indicated by the lower arrow. The addition of
aprotinin at 5 g/ml inhibited complex formation as shown in the right
panel.
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combinant prostasin in 293/Pro and PC-3/Pro cells were easily
released from the membrane with PI-PLC treatment (Figs. 5
and 6A), suggesting that prostasin is bound to the membrane
via a GPI anchor rather than through a true transmembrane
domain. The membrane-bound prostasin in LNCaP cells (native) or DU-145/Pro cells (recombinant), however, was resistant
to PI-PLC treatment (Fig. 6A). As reported in Englund (34) and
Hiroshi et al. (35), not all GPI-anchored proteins are susceptible to PI-PLC digestion. The membrane-anchored prostasin in
LNCaP and DU-145/Pro could potentially be susceptible to
other phospholipases such as GPI-phospholipase D (34, 35).
Our results from the [3H]ethanolamine biosynthetic labeling
experiment with PC-3/Pro and LNCaP cells, however, provided
direct evidence that in the prostate epithelial cells recombinant
or native prostasin is GPI-anchored, regardless of its sensitivity to PI-PLC treatment (Fig. 6B).
Among all four human cell lines that express either recombinant or native prostasin, as well as normal human prostate
tissue, prostasin exists mainly as a membrane-bound protein
(Fig. 6A). A small portion of prostasin in the 293/Pro cells is in
the cytosolic fraction. This cytosolic prostasin could be a misprocessed or misfolded form that was exported from the ER
before GPI anchor attachment, a mechanism documented previously (36). The presumably misfolded prostasin in the cytosol
had no binding activities when it was incubated with mouse
seminal vesicle fluid, possibly because of the misfolding. The
secreted recombinant prostasin, when purified from the 293/
Pro culture medium, however, is enzymatically active and able
to form a complex with mPBP (Figs. 9 and 10), indicating that
the cytosolic prostasin is not the source of secreted prostasin.
The soluble fraction of prostasin seen in the human prostate
tissues (Fig. 6A) before PI-PLC treatment may also be a misfolded form by the same mechanism described above or may be
attributed to residual prostatic fluid caused by possible incomplete washing before tissue lysis.
We identified a PBP in mouse and human seminal vesicles
(Fig. 7). Prostasin forms an 82-kDa, SDS- and heat-stable
complex when incubated with seminal vesicle fluid as determined by SDS-PAGE under reducing conditions followed by
prostasin immunoblotting. This complex is apparently covalently formed between prostasin and PBP and not via a
disulfide linkage. We have chosen to use mouse seminal vesicles for an in-depth analysis of PBP because of easier availability. Complex formation between prostasin and mPBP was inhibited by the polyclonal prostasin antibody, heparin, and
serine protease inhibitors. In a membrane overlay zymography
analysis (Fig. 9), the prostasin-mPBP complex showed no activities to a synthetic substrate D-Pro-Phe-Arg-AFC, whereas
unbound prostasin was active. These results suggest that
mPBP may be a serpin class serine protease inhibitor. The true
nature of the mechanism of prostasin inhibition by mPBP will
be investigated upon purification and sequence analysis of this
protein. An incubation of mouse or human plasma with r-hPro
did not result in formation of any covalently-bound complex.
This result would rule out the possibility of mPBP being one of
the known members of the serpin family present normally in
the blood, such as ␣1-antitrypsin, ␣1-antichymotrypsin, kallistatin, plasminogen activator inhibitor, and protein C inhibitor. At present, the functional significance of PBP with
respect to prostate biology is unclear. Future studies will be
aimed at determining the prostasin binding site in PBP,
which could potentially reveal clues on prostasin’s natural
protein substrate.
One of our goals for the present study was to determine
whether the membrane-anchored prostasin is an active serine
protease. To accomplish this, we needed a prostasin-specific
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(20). In the present study, we intended to investigate the intracellular distribution of prostasin and to determine whether
the cellular prostasin is an active serine protease, to provide
clues to the potential mechanisms of prostasin’s cellular
function.
We first established a mammalian expression system to produce a recombinant human prostasin. The purified secreted
recombinant prostasin displayed biochemical characteristics
similar to those of the native prostasin (purified from human
semen, Ref. 1), such as the molecular mass on SDS-PAGE,
immunological reactivity (Fig. 1), enzymatic activity toward
the synthetic substrate D-Pro-Phe-Arg-AFC (Fig. 9), and responsiveness to serine protease inhibitors (Figs. 8 and 9). We
then used a polyclonal antibody specific for human prostasin to
determine whether prostasin can exist in a membrane-bound
form because its predicted structure suggested this possibility
(2). By means of sequential centrifugation of the 293/Pro and
PC-3/Pro cell components (as shown in Figs. 2 and 3A), we were
able to identify prostasin in various subcellular compartments
such as the crude nuclei, heavy membranes (including mitochondria, lysosomes, and peroxisomes), and light membranes
(including plasma membrane, microsomes, and endoplasmic
reticula). A confocal microscopy analysis of the PC-3/Pro cells
(Fig. 3B) revealed prostasin’s subcellular localization to be
primarily at the nuclear-ER-Golgi complex (27). The immunofluorescently localized prostasin at the nuclear-ER-Golgi complex is believed to be that identified in the Western blot analysis of the nuclear fraction P1. The endogenously expressed
prostasin in the LNCaP cells, however, was only detected in the
light membrane fraction P3 (Fig. 3A) not at the nuclear-ERGolgi complex (Fig. 3B). The different subcellular localization
of prostasin between the recombinant expression system and
the endogenous expression system may be caused by expression level differences. Cells expressing recombinant prostasin
produced high amounts of prostasin with the 293/Pro being the
highest followed by PC-3/Pro and DU-145/Pro. The prostasin
expression level in the LNCaP cells was considerably lower
than that in these transfected cell lines. The expression levels
were determined by a semiquantitative Western blot analysis
(data not shown). Alternatively, different cell lines may have
different protein sorting mechanisms, leading to different subcellular localization patterns (32). On the other hand, GPIanchored prostasin might be associated with sterols and therefore can be found in many compartments of the cell including
the plasma membrane, the Golgi apparatus, ER, nucleus, lysosomes and mitochondria, and in lipid particles (33). Prostasin
in the nuclear fraction (P1) did not show binding activity to
PBP (Fig. 10). It is presently unclear why prostasin in this
fraction was unable to form a complex with mPBP. The functional significance of prostasin in the nuclear-ER-Golgi complex is also unclear at present and will be investigated in the
future.
Despite the apparently different subcellular localization of
prostasin in overexpressing cells versus endogenously expressing cells, prostasin is found in an membrane-bound form in all
cell lines tested as well as in normal human prostate tissues
(Fig. 6A). The membrane-bound prostasin was released when
extracted with a detergent but remained membrane-bound
when treated with high salt or alkali (Fig. 4), ruling out the
possibility that prostasin is associated with another membrane-bound protein via noncovalent linkages. We also demonstrated that the membrane-bound and the detergent-released
prostasin have similar molecular mass (Fig. 4), ruling out the
possibility that prostasin is covalently linked to another membrane-bound protein.
The native prostasin in normal prostate tissue and the re-
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enzymatic activity assay that is applicable for membranebound prostasin because this form of prostasin exists in a
complex mixture. The membrane overlay zymography assay
was not applicable for the membrane-anchored prostasin because lipid-associated proteins cannot be well resolved in nondenaturing native gel electrophoresis. The identification of
mPBP offered us an indirect but prostasin-specific assay to
address this question. As presented in Fig. 10, the membranebound human prostasin also displayed binding activity to
mPBP, and the binding is inhibited by a serine protease inhibitor (aprotinin) that competes for the serine active site, suggesting that the membrane-bound prostasin is likely an active
serine protease. Demonstration of membrane-bound prostasin
being an active serine protease will provide clues for investigating the signal transduction pathway(s) involved in the antiinvasion activity of prostasin because this anti-invasion activity is conferred by the cellular prostasin but not the secreted
prostasin (20).
Prostasin is made in the prostate and secreted as an active
serine protease (1), whereas PBP is made in the seminal vesicles. The fact that prostasin forms a complex with PBP suggests that the two proteins interact with each other when
semen is ejaculated, thereby implicating a role for both proteins in semen coagulation and liquefaction. Prostasin and PBP
in male reproductive tracts may serve together in a partnership
to affect fertility. Investigating the prostasin-PBP partnership
could also lead to a better understanding of the various factors
affecting fertility or, causing infertility. Overall, prostasin, as a
GPI-anchored or a secreted active serine protease, may have
multiple physiological functions, depending on the localization
of the prostasin protein, whether it is membrane-bound or
secreted.
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